1. Home
  2. NEXT vs AUPH Comparison

NEXT vs AUPH Comparison

Compare NEXT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$8.51

Market Cap

2.2B

Sector

Energy

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.98

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
AUPH
Founded
2010
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
NEXT
AUPH
Price
$8.51
$15.98
Analyst Decision
Hold
Buy
Analyst Count
2
4
Target Price
$8.00
$17.25
AVG Volume (30 Days)
2.6M
1.3M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$17.54
Revenue Next Year
N/A
$15.74
P/E Ratio
N/A
$66.00
Revenue Growth
N/A
20.38
52 Week Low
$4.75
$7.29
52 Week High
$12.12
$16.88

Technical Indicators

Market Signals
Indicator
NEXT
AUPH
Relative Strength Index (RSI) 54.49 54.94
Support Level $4.89 $14.53
Resistance Level $8.54 $16.29
Average True Range (ATR) 0.39 0.54
MACD -0.03 0.07
Stochastic Oscillator 48.09 60.52

Price Performance

Historical Comparison
NEXT
AUPH

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: